尿液肽特征可区分膀胱过度活动症并预测治疗后尿失禁改善
OBJECTIVE: To characterize urinary peptide signatures in patients with and without overactive bladder (OAB), identify peptide differences by OAB phenotype, and determine the association between baseline peptide profiles and improvement in incontinence following therapy.…
要点
- OAB患者尿液肽组成与健康对照显著不同,随机森林分类器区分良好(总体AUC 0.76,绝经前亚组AUC 0.91)。
- OAB相关肽特征反映细胞外基质重塑、氧化应激和细胞代谢改变,支持OAB病理生理异质性。
核心结论
- OAB与独特的尿液肽特征相关,该特征反映细胞外基质重塑、氧化应激和细胞代谢改变。
- 基线肽谱在治疗后症状改善者与未改善者之间存在差异,提示尿液肽可能作为预后生物标志物。
研究设计与样本
- 研究纳入152名参与者,包括100例OAB患者和52名健康对照。
- 采用LC-MS/MS进行尿液肽组学分析,使用PEAKS Online软件鉴定肽段。
- 运用经典统计分析和随机森林机器学习分类器区分OAB与对照及治疗应答者与非应答者。
- 参与者基线及治疗后完成经验证问卷。
主要发现
- 纤维蛋白-1和静息巯基氧化酶1来源的肽在OAB中丰度更高。
- 随机森林分类器区分OAB与对照的总体AUC为0.76,绝经前亚组AUC为0.91。
临床怎么用
- 尿液肽谱可能辅助OAB诊断,尤其在绝经前女性中区分能力较好(AUC 0.91)。
- 基线尿液肽谱有望用于预测OAB患者治疗后尿失禁改善情况,指导个体化治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To characterize urinary peptide signatures in patients with and without overactive bladder (OAB), identify peptide differences by OAB phenotype, and determine the association between baseline peptide profiles and improvement in incontinence following therapy. MATERIALS AND METHODS: Peptidomic analysis using LC-MS/MS on urinary samples from 152 participants (100 OAB patients, 52 healthy controls) was performed. Participants completed validated questionnaires at baseline and following treatment. We isolated urinary peptides, analyzed them by mass spectrometry, and identified them using PEAKS Online software. Classical statistical analyses and random forest machine learning classifiers were used to distinguish OAB from controls, and responders vs nonresponders to therapy. RESULTS: The urinary peptidome differed significantly between patients with OAB and controls in overall peptide composition (P = .001) and number of unique peptides (P = .001). Peptides from fibrillin-1 and quiescin sulfhydryl oxidase 1 were more abundant in OAB. Random forest classifiers had good discrimination between OAB and controls (AUC 0.76 overall; 0.91 in premenopausal subset). Baseline peptide composition differed between those who experienced improvement in incontinence vs those who did not experience improvement following therapy in the overall cohort (P = .03) and sacral neuromodulation group (P = .04). CONCLUSION: OAB is associated with a unique urinary peptide signature that reflects extracellular matrix remodeling, oxidative stress, and altered cellular metabolism. Baseline peptide profiles differ between those who symptomatically improved vs did not improve following therapy suggesting potential utility of urinary peptides as prognostic biomarkers. These findings support the heterogeneous nature of OAB pathophysiology and may facilitate development of new diagnostic and personalized therapeutic approaches.
引用
- Miller AW, Jeong SH, McSweeney S, et al. Urinary Peptide Signatures Distinguish Overactive Bladder and Are Associated With Improvement in Incontinence Following Therapy. Urology. 2026. PMID: 42562273. doi:10.1016/j.urology.2026.07.047
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。